首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >microRNA classifiers are powerful diagnostic/prognostic tools in ALK- EGFR- and KRAS-driven lung cancers
【2h】

microRNA classifiers are powerful diagnostic/prognostic tools in ALK- EGFR- and KRAS-driven lung cancers

机译:microRNA分类器是ALKEGFR和KRAS驱动的肺癌的强大诊断/预后工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

microRNAs (miRNAs) can act as oncosuppressors or oncogenes, induce chemoresistance or chemosensitivity, and are major posttranscriptional gene regulators. Anaplastic lymphoma kinase (ALK), EGF receptor (EGFR), and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) are major drivers of non-small cell lung cancer (NSCLC). The aim of this study was to assess the miRNA profiles of NSCLCs driven by translocated ALK, mutant EGFR, or mutant KRAS to find driver-specific diagnostic and prognostic miRNA signatures. A total of 85 formalin-fixed, paraffin-embedded samples were considered: 67 primary NSCLCs and 18 matched normal lung tissues. Of the 67 primary NSCLCs, 17 were echinoderm microtubule-associated protein-like 4–ALK translocated (ALK+) lung cancers; the remaining 50 were not (ALK). Of the 50 ALK primary NSCLCs, 24 were EGFR and KRAS mutation-negative (i.e., WT; triple negative); 11 were mutant EGFR (EGFR+), and 15 were mutant KRAS (KRAS+). We developed a diagnostic classifier that shows how miR-1253, miR-504, and miR-26a-5p expression levels can classify NSCLCs as ALK-translocated, mutant EGFR, or mutant KRAS versus mutation-free. We also generated a prognostic classifier based on miR-769-5p and Let-7d-5p expression levels that can predict overall survival. This classifier showed better performance than the commonly used classifiers based on mutational status. Although it has several limitations, this study shows that miRNA signatures and classifiers have great potential as powerful, cost-effective next-generation tools to improve and complement current genetic tests. Further studies of these miRNAs can help define their roles in NSCLC biology and in identifying best-performing chemotherapy regimens.
机译:microRNA(miRNA)可以作为抑癌基因或致癌基因,诱导化学抗性或化学敏感性,并且是转录后的主要基因调控因子。间变性淋巴瘤激酶(ALK),EGF受体(EGFR)和V-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)是非小细胞肺癌(NSCLC)的主要驱动力。这项研究的目的是评估由易位的ALK,突变的EGFR或突变的KRAS驱动的NSCLC的miRNA谱,以发现驱动程序特异性的诊断和预后miRNA签名。总共考虑了85个福尔马林固定,石蜡包埋的样品:67个原发性NSCLC和18个匹配的正常肺组织。在67例原发性非小细胞肺癌中,有17例是棘皮动物微管相关蛋白样4–ALK易位(ALK + )肺癌。其余的50个不是(ALK -)。在50个ALK -原发性非小细胞肺癌中,有24个为EGFR和KRAS突变阴性(即WT;三阴性)。 11个是突变EGFR(EGFR + ),15个是突变KRAS(KRAS + )。我们开发了一种诊断分类器,显示了miR-1253,miR-504和miR-26a-5p表达水平如何将NSCLC分类为 ALK 易位,突变体 EGFR 或突变体 KRAS 与无突变。我们还基于miR-769-5p和Let-7d-5p表达水平生成了可预测整体生存的预后分类器。该分类器显示出比基于突变状态的常用分类器更好的性能。尽管它有几个局限性,但这项研究表明,miRNA签名和分类器作为强大的,具有成本效益的下一代工具,具有巨大的潜力,可以改进和补充当前的基因检测。这些miRNA的进一步研究可以帮助确定它们在NSCLC生物学中的作用以及确定最佳化疗方案的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号